Preclinical Discovery and Development of New Compounds as HPK1 Inhibitors for Cancer Treatment
Abstract:
The overall objective of the project is to discover and develop new HPK1 inhibitors at the preclinical level, with therapeutic potential in oncology. To achieve this, key stages will be addressed, including the design, synthesis, and optimization of compounds, evaluation of ADME properties, in vitro and in vivo efficacy studies, synthesis scale-up, and patent applications.
The project will be carried out by a consortium composed of Medchemfarma, Leitat, and the University of Santiago de Compostela (USC), combining expertise in medicinal chemistry, pharmacology, and early drug discovery. Specialized service providers will also be subcontracted for specific stages of the development.
This project aligns with the objectives of the Recovery, Transformation, and Resilience Plan (PRTR), strengthening R&D in health. A Technical Steering Committee will coordinate the work, ensuring the achievement of objectives, the protection of results, and their proper dissemination.
Leitat’s role in the project:
Leitat will act as a beneficiary partner in the HPK1-INHIB project.
Project budget: 896.221,99€
Financial framework: Proyectos de colaboración público-privada 2022
Start date: 01/03/2023
Leitat’s budget: 200.396,63€
Contract number: CPP2022-009716
End date: 28/02/2026
Partners:
Project CPP2022-009716 funded by:
